First Light Asset Management LLC Purchases 410,603 Shares of Simulations Plus, Inc. $SLP

First Light Asset Management LLC raised its position in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 115.0% during the third quarter, HoldingsChannel reports. The firm owned 767,760 shares of the technology company’s stock after purchasing an additional 410,603 shares during the period. First Light Asset Management LLC’s holdings in Simulations Plus were worth $11,570,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SLP. North Star Investment Management Corp. increased its position in shares of Simulations Plus by 195.6% during the 3rd quarter. North Star Investment Management Corp. now owns 168,130 shares of the technology company’s stock valued at $2,534,000 after purchasing an additional 111,255 shares during the last quarter. Tributary Capital Management LLC raised its holdings in shares of Simulations Plus by 214.7% during the 3rd quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock valued at $17,134,000 after buying an additional 775,704 shares in the last quarter. Royce & Associates LP lifted its position in Simulations Plus by 31.6% in the 3rd quarter. Royce & Associates LP now owns 348,758 shares of the technology company’s stock worth $5,256,000 after buying an additional 83,758 shares during the last quarter. Stephens Investment Management Group LLC boosted its stake in Simulations Plus by 46.3% in the third quarter. Stephens Investment Management Group LLC now owns 392,840 shares of the technology company’s stock worth $5,920,000 after buying an additional 124,264 shares in the last quarter. Finally, Herald Investment Management Ltd purchased a new stake in Simulations Plus in the third quarter worth approximately $3,016,000. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Price Performance

SLP stock opened at $12.44 on Monday. Simulations Plus, Inc. has a 1 year low of $11.16 and a 1 year high of $36.45. The firm has a 50-day moving average of $15.47 and a 200 day moving average of $16.35. The company has a market cap of $250.67 million, a P/E ratio of -3.89 and a beta of 1.18.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Thursday, January 8th. The technology company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.05). Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. The firm had revenue of $18.42 million for the quarter, compared to the consensus estimate of $18.05 million. During the same period in the previous year, the firm posted $0.17 earnings per share. On average, equities research analysts expect that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. TD Cowen reissued a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. Citigroup reaffirmed a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. BTIG Research lowered shares of Simulations Plus from a “buy” rating to a “neutral” rating in a report on Thursday, December 18th. Finally, Zacks Research cut shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. Three equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $25.00.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.